Publicação:
Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia?

dc.contributor.authorSun, Sue Yazaki
dc.contributor.authorMelamed, Alexander
dc.contributor.authorGoldstein, Donald P.
dc.contributor.authorBernstein, Marilyn R.
dc.contributor.authorHorowitz, Neil S.
dc.contributor.authorMoron, Antonio Fernandes
dc.contributor.authorMaesta, Izildinha [UNESP]
dc.contributor.authorBraga, Antonio
dc.contributor.authorBerkowitz, Ross S.
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionBrigham &Womens Hosp
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionDonald P Goldstein MD Trophoblast Tumor Registry
dc.contributor.institutionUniversidade Federal do Rio de Janeiro (UFRJ)
dc.contributor.institutionUniversidade Federal Fluminense (UFF)
dc.contributor.institutionHarvard Canc Ctr
dc.contributor.institutionHarvard Univ
dc.date.accessioned2015-10-21T13:09:11Z
dc.date.available2015-10-21T13:09:11Z
dc.date.issued2015-07-01
dc.description.abstractObjective. To compare the clinical presentation and incidence of postmolar gestational trophoblastic neoplasia (GTN) among recent (1994-2013) and historical (1988-1993) cases of complete hydatidiform mole (CHM).Methods. This study included two non-concurrent cohorts (1988-1993 versus 1994-2013) of patients from the New England Trophoblastic Disease Center (NETDC). Clinical and pathologic reports of patients diagnosed with CHM between 1994 and 2013 were reviewed. Gestational age at evacuation, features of clinical presentation, human chorionic gonadotropin (hCG) levels, and the rate of progression to GTN were compared.Results. In the current cohort (1994 to 2013) the median gestational age at diagnosis continued to decline compared to our prior cohort (1988-1993) (9 weeks versus 12 weeks). Patients from the current cohort were significantly more likely to be diagnosed prior to the 11th week of gestation (56 versus 41%, p = 0.04). Patients in the current cohort were also significantly less likely to present with vaginal bleeding (46 versus 84%, p < 0.001). Earlier diagnosis of complete mole did not result in a decrease in the rate of postmolar GTN. The frequencies of postmolar GTN in the current (1994-2013) and prior (1988-1993) cohorts were 19 and 23%, respectively. In the current cohort, even diagnosis prior to ten weeks gestation did not decrease the risk of developing GTN.Conclusions. This study indicates that complete mole continues to be diagnosed progressively earlier resulting in a further decrease in some classical presenting symptoms. However, despite earlier detection, the risk of development of postmolar GTN has not been affected. (C) 2015 Elsevier Inc. All rights reserved.en
dc.description.affiliationUNIFESP Sao Paulo Fed Univ, Paulista Sch Med, Dept Obstet, Sao Paulo, SP, Brazil
dc.description.affiliationBrigham &Womens Hosp, Dept Obstet &Gynecol, Div Gynecol Oncol, Boston, MA 02115 USA
dc.description.affiliationUNESP Sao Paulo State Univ, Botucatu Med Sch, Dept Gynecol &Obstet, Botucatu, SP, Brazil
dc.description.affiliationDonald P Goldstein MD Trophoblast Tumor Registry, New England Trophoblast Dis Ctr, Boston, MA USA
dc.description.affiliationUNIFESP Sao Paulo Fed Univ, Paulista Sch Med, Trophoblast Dis Ctr, Sao Paulo Hosp, Sao Paulo, SP, Brazil
dc.description.affiliationUNESP Sao Paulo State Univ, Botucatu Med Sch, Trophoblast Dis Ctr, Botucatu, SP, Brazil
dc.description.affiliationUniv Fed Rio de Janeiro, Matern Sch, Trophoblast Dis Ctr, Rio De Janeiro, Brazil
dc.description.affiliationUniv Fed Fluminense, Antonio Pedro Univ Hosp, Trophoblast Dis Ctr, Rio De Janeiro, Brazil
dc.description.affiliationHarvard Canc Ctr, Dana Farber Canc Inst, Boston, MA USA
dc.description.affiliationHarvard Univ, Sch Med, Boston, MA USA
dc.description.affiliationUnespUNESP Sao Paulo State Univ, Botucatu Med Sch, Dept Gynecol &Obstet, Botucatu, SP, Brazil
dc.description.affiliationUnespUNESP Sao Paulo State Univ, Botucatu Med Sch, Trophoblast Dis Ctr, Botucatu, SP, Brazil
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipDyett Family Trophoblastic Disease Research and Registry Endowment
dc.description.sponsorshipIdCNPq: 200756/2014-1
dc.format.extent46-49
dc.identifierhttp://www.sciencedirect.com/science/article/pii/S0090825815008719
dc.identifier.citationGynecologic Oncology. San Diego: Academic Press Inc Elsevier Science, v. 138, n. 1, p. 46-49, 2015.
dc.identifier.doi10.1016/j.ygyno.2015.05.002
dc.identifier.issn0090-8258
dc.identifier.lattes9012667997804219
dc.identifier.urihttp://hdl.handle.net/11449/128349
dc.identifier.wosWOS:000356841100008
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofGynecologic Oncology
dc.relation.ispartofjcr4.540
dc.relation.ispartofsjr2,339
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjectGestational trophoblastic diseaseen
dc.subjectGestational trophoblastic neoplasiaen
dc.titleChanging presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia?en
dc.typeArtigo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dcterms.rightsHolderElsevier B.V.
dspace.entity.typePublication
unesp.author.lattes9012667997804219
unesp.author.orcid0000-0001-6573-7386[1]
unesp.author.orcid0000-0002-0654-0863[2]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt
unesp.departmentGinecologia e Obstetrícia - FMBpt

Arquivos